MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial

MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company, has announced a private placement agreement to raise approximately $695,000. The company will issue 463,332 shares of common stock at $1.50 per share to accredited investors and a company director, with each share accompanied by a warrant to purchase an additional share at $1.71. The warrants will become exercisable six months after issuance and will remain valid for five years.

The proceeds will primarily support Step 1 of Part C in the MAIA Biotechnology, Inc. (NYSE:MAIA)’s ongoing Phase II THIO-101 trial, which focuses on innovative targeted immunotherapies for cancer, as well as general working capital needs. Shares and warrants issued to the company director will be under MAIA Biotechnology, Inc. (NYSE:MAIA)’s 2021 Equity Incentive Plan.

A doctor in a laboratory conducting research on a petri dish, with biotechnology equipment in the background.

This offering is being conducted as a private placement under Section 4(a)(2) of the Securities Act and Regulation D, meaning the securities and underlying shares are unregistered and cannot be sold in the U.S. without meeting specific legal exemptions. The transaction is expected to close around May 29, 2025, pending customary conditions. This announcement does not constitute an offer or solicitation to buy or sell these securities.

While we acknowledge the potential of MAIA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than MAIA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.